Page 3 - Long Acting Suppression News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Long acting suppression. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Long Acting Suppression Today - Breaking & Trending Today

GSK's ViiV Healthcare receives Marketing Authorisation of HIV treatment Vocabria in Europe


7:35 am
GlaxoSmithKline plc (LON:GSK), with Pfizer Inc. and Shionogi Limited as shareholders, has announced ViiV Healthcare, the global specialist HIV company, announced the authorisation of Vocabria (cabotegravir injection and tablets) in combination with Janssen Pharmaceutical Companies of Johnson & Johnson’s Rekambys (rilpivirine injection) and Edurant (rilpivirine tablets), in the European Union, for the treatment of HIV-1 infection in adults who are virologically suppressed. Cabotegravir injection is indicated, in combination with rilpivirine injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA ....

Santiago De Compostela , Antonio Antela , Deborah Waterhouse , Drug Administration , Janssen Pharmaceutical Companies Of Johnson Rekambys , University Hospital , Pfizer Inc , European Union , Health Canada , Shionogi Limited , Viiv Healthcare , Janssen Pharmaceutical Companies , Human Immunodeficiency Virus , Positive Perspectives Wave , Antiretroviral Therapy , Long Acting Suppression , First Long Acting Injectable Regimen , Health Care Professional , New Drug Application , ஸ்யாஂடியாகொ டி கம்போஸ்டெலா , அன்டோனியோ ஆன்டெலா , டெபோரா வாட்டர்ஹவுஸ் , பல்கலைக்கழகம் மருத்துவமனை , ஃபைசர் இன்க் , ஐரோப்பிய தொழிற்சங்கம் , ஆரோக்கியம் கனடா ,

Injectable HIV treatment that can be taken bi-monthly approved by the EU


A doctor holds needles. (KERRY SHERIDAN/AFP/Getty)
The European Union has approved a groundbreaking treatment for HIV – the first complete, long-lasting and once or bi-monthly injectable – in what activists have hailed as a “game-changer”.
American drug-maker ViiV Healthcare, which specialises in HIV, announced Monday (21 December) that the European Commission gas had rubber-stumped the revolutionary, long-acting regimen, after it was first submitted to the bloc’s medicine authority last year.
The treatment consists of two drugs known as cabotegravir and rilpivirine, the latter developed by Janssen Pharmaceutical Companies, that are injected once a month, or once every other month, by a healthcare provider into the buttocks. ....

United States , United Kingdom , Deborah Waterhouse , Matthew Hodson , European Union , European Commission , Janssen Pharmaceutical Companies , Viiv Healthcare , Antiretroviral Therapy , Long Acting Suppression , First Long Acting Injectable Regimen , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , டெபோரா வாட்டர்ஹவுஸ் , மேத்யூ ஹாட்சன் , ஐரோப்பிய தொழிற்சங்கம் , ஐரோப்பிய தரகு , ஜான்சன் மருந்து நிறுவனங்கள் , ஆன்டிரெட்ரோவைரல் சிகிச்சை , நீண்டது நடிப்பு அடக்குமுறை ,